News
Health Canada approves biosimilar Niopeg (a pegylated form of filgrastim) in Canada.--Nora Pharma
Nora Pharma, a Canadian pharmaceutical company, has received approval for its first biosimilar product. Nora Pharma, a wholly owned division of Sunshine Biopharma, has received approval from Health Canada for the commercialization of Niopeg (a pegylated form of filgrastim) in Canada.
Niopeg is a Biosimilar comparable to the reference biologic drug Neulasta (pegfilgrastim). Niopeg is a long-acting form of recombinant human granulocyte colony-stimulating factor (r-HuG-CSF), or filgrastim. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs. Niopeg is available in a pre-filled syringe of 6 mg/0.6 mL.
Condition: Neutropenia
Type: drug